ofa tirzepatide FDA Says Compounded Must Exit the Market Tirzepatide for Medical Weight Loss

CJC-1295 vs Other GH-Axis Peptides: Side-Effect Comparison Who Shouldn't Use CJC-1295 Active cancer or a personal/family history of hormone-sensitive cancers (breast, prostate, colorectal) without oncologist clearance Uncontrolled type 2 diabetes or a recent hypoglycaemic event Untreated hypothyroidism, which blunts the GH axis response and can mask dosing feedback Pregnancy or breastfeeding

Common adverse effects include gastrointestinal symptoms such as nausea, vomiting, diarrhoea, and constipation, particularly during dose escalation

Choi W, Lee J, Lee J, Lee SH, Dim S

ThinEra delivers doctor supervised weight loss through a structured medical weight loss program, not just prescription access